Why ChemAI?
At ChemAI, we believe in building long-term partnerships, not conventional customer-vendor relationships. Our model is designed for organizations that see AI not just as a tool, but as a strategic enabler in chemical and pharmaceutical R&D. Rather than offering off-the-shelf solutions, we work closely with our partners to co-develop and integrate ChemAI’s predictive technology into their workflows – aligning deeply with scientific goals, operational needs, and existing infrastructure such as ELNs, LIMS, and lab automation platforms.
A key part of this value lies in the depth and uniqueness of our data foundation. ChemAI’s models are trained on a curated, proprietary dataset that combines best in class reaction data with millions of expert-annotated and partner-contributed records – capturing the subtle, real-world complexity of chemical processes. This allows us to deliver more accurate, mechanistically informed predictions that reflect the actual conditions and outcomes chemists care about. By continuously expanding and refining our data in collaboration with partners, we ensure our technology evolves alongside your science.
Our partnership models include:
Enterprise Licensing: Scalable access to the SmartChemistry® platform, supporting multi-team, multi-project use across discovery and development functions.
Custom Integrations: Embedding our models directly into internal systems to support real-time decision-making and data flow.
Joint Development Projects: Collaborative initiatives to design and build tailored solutions for specific R&D challenges.
This partnership-first approach allows us to create greater value, ensure lasting impact, and support innovation at every stage of the research pipeline.
At ChemAI, our strength lies not only in our technology but in the people behind it. From our world-class executive leadership and board to our deeply experienced technical team and globally respected scientific advisors, we bring together the expertise needed to solve the toughest challenges in chemistry. Our collective experience spans pharmaceutical R&D, AI, data science, and chemical informatics – enabling us to build intelligent, scalable tools that deliver real impact for our customers.
ChemAI’s executive team brings world-class operational and scientific leadership from across the pharmaceutical, chemical, and technology sectors. With a proven track record in building and scaling AI-driven and scientific organizations, they lead with deep domain expertise, executional excellence, and a strong focus on delivering customer impact. Their experience spans medicinal chemistry, cheminformatics, data infrastructure, and enterprise software – ensuring ChemAI’s platform delivers real-world value in complex R&D environments.
Dr. Mark Warne, Chief Executive Officer
Dr. Mark Warne is the Chief Executive Officer of ChemAI, bringing over two decades of leadership experience in life sciences, technology commercialization, and venture-backed innovation. Prior to joining ChemAI, he served nearly a decade at IP Group plc, a leading intellectual property commercialization company, where he led the Healthcare team and managed a portfolio of healthcare investments. Mark has held executive and board roles across numerous biotech and digital health companies, including as Non-Executive Chairman of IXICO plc, and advisory roles at Angelini Ventures. He holds a Ph.D. in Computational Chemistry from the University of Bristol and is a Chartered Chemist and member of the Royal Society of Chemistry.
Dr. Thomas Galeandro-Diamant, Chief Technology Officer
Dr. Thomas Galeandro-Diamant is the Chief Technology Officer at ChemAI, where he leads the development of advanced AI technologies for predictive chemistry. With a Ph.D. in chemistry focused on nanostructured catalysts for alkene hydrosilylation, Thomas brings deep scientific expertise in organic chemistry, catalysis, and cheminformatics. He previously founded Chemintelligence, a company specializing in AI-based software for chemical and materials R&D, which was acquired by ChemAI in 2022. Prior to that, he worked at Solvay’s Research and Innovation Center in Lyon. Thomas has authored multiple scientific publications and holds a patent in catalysis.
Jenny Hand, Chief of Staff and Company Secretary
Jenny Hand is Chief of Staff and Company Secretary at ChemAI, where she drives strategic initiatives and operational excellence across the organization. With a strong background in organizational leadership, governance, and compliance, she works closely with the executive team to align ChemAI’s vision, streamline internal processes, and support a high-performing, inclusive culture. Passionate about enabling innovation in chemistry, Jenny brings expertise in cross-functional coordination, project execution, and corporate governance – ensuring that ChemAI operates with both integrity and impact.
Our board comprises seasoned leaders from top-tier pharma, venture-backed technology, and academic research institutions. They provide strategic oversight, industry perspective, and long-term vision – helping to guide ChemAI through key growth milestones. With backgrounds in company-building, investment, and scientific innovation, the board ensures ChemAI stays aligned with the evolving needs of the chemical and pharmaceutical industries while scaling responsibly.
Dave Norwood, Non-Executive Chairman
David Norwood is a British entrepreneur, investor, and philanthropist with a distinguished career in science commercialization and innovation. He co-founded Oxford Sciences Innovation (now Oxford Science Enterprises), a £1.2 billion venture capital firm that partners with the University of Oxford to transform academic research into commercial ventures. Prior to this, he founded IP Group plc, focusing on investments in spinouts from Oxford University’s Chemistry Department. Norwood’s leadership has been instrumental in bridging the gap between cutting-edge scientific research and practical, real-world applications. As Chairman of ChemAI, he brings his extensive experience in science-driven entrepreneurship to guide the company’s strategic direction and growth
Alan Aubrey, Non-Executive Director
Alan Aubrey is a Non-Executive Director at ChemAI, bringing decades of experience in science commercialization and venture building. As the former CEO of IP Group plc, he helped scale the FTSE 250 company into a leading investor in university spin-outs across pharmaceuticals, diagnostics, and clean energy. He previously co-founded Techtran Group Ltd, a pioneering technology transfer business acquired by IP Group in 2005. In addition to his board role at ChemAI, Alan has held senior positions across several science and technology companies, as well as contributing to UK innovation policy as a Non-Executive Board Member for the Department for Business, Innovation & Skills.
Dr Tony De Fourgerolles, Non-Executive Director
Dr. Antonin de Fougerolles is a seasoned biotech executive and scientific innovator with over 25 years of experience in developing and advancing novel drug modalities. He has played pivotal roles in the success of several groundbreaking therapies, including RNA interference (RNAi), messenger RNA (mRNA), and single-domain antibodies. As the founding Chief Scientific Officer at Moderna Therapeutics, Tony was instrumental in pioneering mRNA-based therapeutics.
Tony holds a Ph.D. in Immunology from Harvard University and a B.Sc. in Microbiology & Immunology from McGill University. He currently serves on the boards of several biotech companies, including eTheRNA, Chimeron Bio, and Walking Fish Therapeutics, and is a Non-Executive Director at ChemAI.
Dr Bryn Roberts, Non-Executive Director & Scientific Advisor
Dr. Bryn Roberts is a seasoned leader in pharmaceutical data science and informatics, currently serving as Global Head of Data, Analytics & Research at Roche Information Solutions. With over 25 years of experience spanning roles at Organon, Zeneca, AstraZeneca, and Roche, he has driven innovation in data strategy, AI, and digital health. At ChemAI, Bryn contributes his deep expertise in data-driven R&D, helping shape the company’s scientific direction and platform development. He also serves on the Swiss Science Council and holds academic appointments at the University of Bristol and the University of Oxford, reflecting his commitment to advancing science and technology.
Mirko Walter, Non-Executive Director
Mirko Walter is a seasoned commercial leader in scientific publishing and digital transformation. As Senior Vice President of Sales at Springer Nature, he oversees global solution sales across corporate markets, helping organizations access and apply scientific knowledge at scale. Mirko brings deep expertise in data-driven business models, enterprise partnerships, and the commercialization of research tools. As a Non-Executive Director at ChemAI, he contributes strategic insight on market development, customer engagement, and scaling AI-enabled platforms in the scientific domain.
ChemAI’s scientific advisors are globally recognized experts in chemistry, machine learning, and data-driven drug discovery. With deep academic and industry experience, they help shape the scientific direction of our platform, ensuring it is grounded in rigorous methodology and aligned with real-world R&D needs. Their insights guide everything from model design to validation strategies, enabling ChemAI to deliver scientifically robust, high-impact solutions for our customers.
The ChemAI team brings together deep expertise in chemistry, data science, and AI. Our scientists, data engineers, and machine learning researchers have decades of combined experience across industry and academia, including drug discovery, chemical informatics, and large-scale model development. With a rare blend of domain knowledge and technical skill, our team is uniquely positioned to build tools that truly understand chemistry – delivering practical, high-impact solutions for the world’s leading R&D organizations.
Our Mission
At ChemAI, our mission is to transform how the world discovers and develops chemistry. We harness the power of unique data, proprietary AI, and deep scientific expertise to accelerate innovation, reduce waste, and enable more intelligent, sustainable chemical R&D.
Our Vision
We envision a world where predictive chemistry empowers scientists to solve the most complex challenges in pharmaceuticals, materials, and beyond – faster, smarter, and more responsibly.
Our Values
▪ Scientific Integrity – We ground everything we build in rigorous science, trusting in mechanisms, data, and validation — not hype.
▪ Partnership-First – We build long-term relationships, not transactions. We work side-by-side with our partners to co-create value and deliver real-world impact.
▪ Precision-Driven – We aim for accuracy in our models, clarity in our communication, and excellence in our outcomes.
▪ Data as a Foundation – We believe that well-structured, high-quality data – curated and contextualized – is the cornerstone of breakthrough innovation.
▪ Curiosity & Continuous Learning – We’re always learning, iterating, and improving in our science, our systems, and ourselves.
▪ Responsibility – We take ownership of our work and its impact – on our partners, our team, and the planet.
▪ Inclusivity -We foster a collaborative, respectful culture where diverse ideas and backgrounds drive better outcomes.
What are the benefits of partnering with ChemAI?
Accelerated R&D
ChemAI significantly shortens development timelines by predicting reaction outcomes in advance, enabling faster lead optimization and synthesis planning.
Better Decision-Making
Our domain-specific AI, powered by unique chemical data, delivers accurate, mechanism-aware predictions to support confident, data-driven choices.
Smarter Experimentation
AI-guided design and multi-parameter optimization reduce trial-and-error, focusing resources on high-value experiments.
Seamless Integration & Security
Built to integrate with ELNs, LIMS, and internal systems, ChemAI aligns with ISO standards to ensure data security and compliance.
Cost and Sustainability Gains
Fewer failed experiments and optimized conditions lead to lower costs, reduced waste, and more sustainable chemistry.
Our security principles:
At ChemAI, data security is a core priority. We align our infrastructure and practices with internationally recognized standards, including ISO/IEC 27001, to ensure the confidentiality, integrity, and availability of your data. All customer information, experimental results, and proprietary datasets are handled with strict access controls, encryption protocols, and secure cloud architecture.
We continuously monitor and update our systems to maintain compliance with industry best practices, enabling our partners to innovate with confidence while knowing their sensitive data is protected.
Why does it matter to our partners?
For our customers (particularly in the pharmaceutical, chemical, and materials industries) data security is not optional; it’s fundamental. Whether protecting proprietary compound libraries, confidential reaction data, or regulated development workflows, ChemAI ensures that sensitive IP remains secure at every stage.
By providing a trusted, compliant platform, we allow R&D teams to collaborate, experiment, and scale with peace of mind – without compromising data integrity or ownership.